Polycystic ovary syndrome metabolic and hormonal dysfunction in relation to osteoarthritis onset and development: innocent bystander or major risk factor?
PDF EN
PDF BG

Keywords

osteoarthritis
knee osteoarthritis
polycystic ovary syndrome
obesity

How to Cite

[1]
Georgiev, T. and Kabakchieva, P. 2021. Polycystic ovary syndrome metabolic and hormonal dysfunction in relation to osteoarthritis onset and development: innocent bystander or major risk factor?. Rheumatology (Bulgaria). 29, 2 (Jul. 2021), 40-51. DOI:https://doi.org/10.35465/29.2.2021.pp40-51.

Abstract

The close link between osteoarthritis (OA) and metabolic disorders on the one hand and hormonal disorders on the other suggests a possible association between OA and endocrine-metabolic disorders, such as PCOS. The aim of this review is to analyze the relationship between PCOS and OA, to consider the common pathogenetic mechanisms between the two conditions, and to summarize the data accumulated so far in the literature. For the purposes of our narrative review, a comprehensive search was conducted within credible databases. Our literature search found that epidemiological studies have shown a higher incidence of knee and hip OA in women with PCOS. This can be partly explained by obesity, which is a common intersection between the two conditions. Potential mechanisms among OA, PCOS, and obesity were considered. Another common point between OA and PCOS is that both conditions can be considered as highly heterogeneous syndromes with various etiologies, the result of a combination of systemic (genetic, hormonal, and metabolic) and local factors. To date, hyperandrogenism and greater cartilage thickness in young women with PCOS remain unclear in terms of determining the risk of developing OA. Prospective longitudinal studies are needed to assess the “fate” of the weight-bearing joints in women with PCOS, who are more likely to suffer from knee joint complaints.
https://doi.org/10.35465/29.2.2021.pp40-51
PDF EN
PDF BG

References

  1. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, Lizneva D, Natterson-Horowtiz B, Teede HJ, Yildiz BO. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016 Aug 11;2:16057. doi: 10.1038/nrdp.2016.57.
  2. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev. 1999 Aug;20(4):535-82. doi: 10.1210/edrv.20.4.0374.
  3. Hameed I, Masoodi SR, Mir SA, Nabi M, Ghazanfar K, Ganai BA. Type 2 diabetes mellitus: From a metabolic disorder to an inflammatory condition. World J Diabetes. 2015 May 15;6(4):598-612. doi: 10.4239/wjd.v6.i4.598.
  4. Pedrinelli R, Dell'Omo G, Di Bello V, Pellegrini G, Pucci L, Del Prato S, Penno G. Low-grade inflammation and microalbuminuria in hypertension. Arterioscler Thromb Vasc Biol. 2004 Dec;24(12):2414-9. doi: 10.1161/01.ATV.0000147415.40692.7f.
  5. Gateva A, Kamenov Z. Cardiovascular Risk Factors in Bulgarian Patients with Polycystic Ovary Syndrome and/or Obesity. Obstet Gynecol Int. 2012;2012:306347. doi: 10.1155/2012/306347.
  6. Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 2012 Jun;64(6):1697-707. doi: 10.1002/art.34453.
  7. Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage. 2013 Jan;21(1):16-21. doi: 10.1016/j.joca.2012.11.012.
  8. Jang S, Lee K, Ju JH. Recent Updates of Diagnosis, Pathophysiology, and Treatment on Osteoarthritis of the Knee. Int J Mol Sci. 2021 Mar 5;22(5):2619. doi: 10.3390/ijms22052619.
  9. Bay-Jensen AC, Hoegh-Madsen S, Dam E, Henriksen K, Sondergaard BC, Pastoureau P, Qvist P, Karsdal MA. Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis? Rheumatol Int. 2010 Feb;30(4):435-42. doi: 10.1007/s00296-009-1183-1.
  10. Georgiev T. Multimodal approach to intraarticular drug delivery in knee osteoarthritis. Rheumatol Int. 2020 Nov;40(11):1763-1769. doi: 10.1007/s00296-020-04681-7.
  11. Sharmeen S, Nomani H, Taub E, Carlson H, Yao Q. Polycystic ovary syndrome: epidemiologic assessment of prevalence of systemic rheumatic and autoimmune diseases. Clin Rheumatol. 2021 Jul 3. doi: 10.1007/s10067-021-05850-0.
  12. Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD. Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int. 2011 Nov;31(11):1409-17. doi: 10.1007/s00296-011-1999-3.
  13. Blundell JE, Baker JL, Boyland E, Blaak E, Charzewska J, de Henauw S, Frühbeck G, Gonzalez-Gross M, Hebebrand J, Holm L, Kriaucioniene V, Lissner L, Oppert JM, Schindler K, Silva AL, Woodward E. Variations in the Prevalence of Obesity Among European Countries, and a Consideration of Possible Causes. Obes Facts. 2017;10(1):25-37. doi: 10.1159/000455952.
  14. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004 Jun;89(6):2548-56. doi: 10.1210/jc.2004-0395.
  15. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH; American Heart Association; Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006 Feb 14;113(6):898-918. doi: 10.1161/CIRCULATIONAHA.106.171016.
  16. Fantuzzi G, Mazzone T. Adipose tissue and atherosclerosis: exploring the connection. Arterioscler Thromb Vasc Biol. 2007 May;27(5):996-1003. doi: 10.1161/ATVBAHA.106.131755.
  17. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2001 Jun;86(6):2453-5. doi: 10.1210/jcem.86.6.7580.
  18. Escobar-Morreale HF, Luque-Ramírez M, González F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril. 2011 Mar 1;95(3):1048-58.e1-2. doi: 10.1016/j.fertnstert.2010.11.036.
  19. Alissa EM, Algarni SA, Khaffji AJ, Al Mansouri NM. Impact of interlukin-6 on central obesity measures in women with polycystic ovarian syndrome. J Obstet Gynaecol. 2020 Nov;40(8):1133-1137. doi: 10.1080/01443615.2019.1697219.
  20. Escobar-Morreale HF, Botella-Carretero JI, Villuendas G, Sancho J, San Millán JL. Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity. J Clin Endocrinol Metab. 2004 Feb;89(2):806-11. doi: 10.1210/jc.2003-031365.
  21. Zhang YF, Yang YS, Hong J, Gu WQ, Shen CF, Xu M, Du PF, Li XY, Ning G. Elevated serum levels of interleukin-18 are associated with insulin resistance in women with polycystic ovary syndrome. Endocrine. 2006 Jun;29(3):419-23. doi: 10.1385/ENDO:29:3:419.
  22. Dawood A, Alkafrawy N, Saleh S, Noreldin R, Zewain S. The relationship between IL-18 and atherosclerotic cardiovascular risk in Egyptian lean women with polycystic ovary syndrome. Gynecol Endocrinol. 2018 Apr;34(4):294-297. doi: 10.1080/09513590.2017.1395835.
  23. González F, Rote NS, Minium J, Kirwan JP. Evidence of proatherogenic inflammation in polycystic ovary syndrome. Metabolism. 2009 Jul;58(7):954-62. doi: 10.1016/j.metabol.2009.02.022.
  24. Glintborg D, Andersen M, Richelsen B, Bruun JM. Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1alpha are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment. Clin Endocrinol (Oxf). 2009 Nov;71(5):652-8. doi: 10.1111/j.1365-2265.2009.03523.x.
  25. Hu W, Qiao J, Yang Y, Wang L, Li R. Elevated C-reactive protein and monocyte chemoattractant protein-1 in patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2011 Jul;157(1):53-6. doi: 10.1016/j.ejogrb.2011.03.015.
  26. Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, Baron AD. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation. 2001 Mar 13;103(10):1410-5. doi: 10.1161/01.cir.103.10.1410.
  27. Carmina E, Orio F, Palomba S, Longo RA, Cascella T, Colao A, Lombardi G, Rini GB, Lobo RA. Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med. 2006 Apr;119(4):356.e1-6. doi: 10.1016/j.amjmed.2005.10.059.
  28. Sabuncu T, Vural H, Harma M, Harma M. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem. 2001 Jul;34(5):407-13. doi: 10.1016/s0009-9120(01)00245-4.
  29. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012 Dec;33(6):981-1030. doi: 10.1210/er.2011-1034.
  30. Gambineri A, Laudisio D, Marocco C, Radellini S, Colao A, Savastano S; Obesity Programs of nutrition, Education, Research and Assessment (OPERA) group. Female infertility: which role for obesity? Int J Obes Suppl. 2019 Apr;9(1):65-72. doi: 10.1038/s41367-019-0009-1.
  31. Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG. 2006 Oct;113(10):1148-59. doi: 10.1111/j.1471-0528.2006.00990.x.
  32. Kirschner MA, Samojlik E, Drejka M, Szmal E, Schneider G, Ertel N. Androgen-estrogen metabolism in women with upper body versus lower body obesity. J Clin Endocrinol Metab. 1990 Feb;70(2):473-9. doi: 10.1210/jcem-70-2-473.
  33. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord. 2002 Jul;26(7):883-96. doi: 10.1038/sj.ijo.0801994.
  34. Romero-Corral A, Somers VK, Sierra-Johnson J, Jensen MD, Thomas RJ, Squires RW, Allison TG, Korinek J, Lopez-Jimenez F. Diagnostic performance of body mass index to detect obesity in patients with coronary artery disease. Eur Heart J. 2007 Sep;28(17):2087-93. doi: 10.1093/eurheartj/ehm243.
  35. Coutinho T, Goel K, Corrêa de Sá D, Kragelund C, Kanaya AM, Zeller M, Park JS, Kober L, Torp-Pedersen C, Cottin Y, Lorgis L, Lee SH, Kim YJ, Thomas R, Roger VL, Somers VK, Lopez-Jimenez F. Central obesity and survival in subjects with coronary artery disease: a systematic review of the literature and collaborative analysis with individual subject data. J Am Coll Cardiol. 2011 May 10;57(19):1877-86. doi: 10.1016/j.jacc.2010.11.058.
  36. Gateva AT, Kamenov ZA. Markers of visceral obesity and cardiovascular risk in patients with polycystic ovarian syndrome. Eur J Obstet Gynecol Reprod Biol. 2012 Oct;164(2):161-6. doi: 10.1016/j.ejogrb.2012.05.037.
  37. Georgiev T. Clinical characteristics and disability in patients with knee osteoarthritis: real world experience from Bulgaria. Reumatologia. 2019;57(2):78-84. doi: 10.5114/reum.2019.84812.
  38. Hart HF, van Middelkoop M, Stefanik JJ, Crossley KM, Bierma-Zeinstra S. Obesity is related to incidence of patellofemoral osteoarthritis: the Cohort Hip and Cohort Knee (CHECK) study. Rheumatol Int. 2020 Feb;40(2):227-232. doi: 10.1007/s00296-019-04472-9.
  39. Georgiev T, Angelov AK. Modifiable risk factors in knee osteoarthritis: treatment implications. Rheumatol Int. 2019 Jul;39(7):1145-1157. Doi: 10.1007/s00296-019-04290-z.
  40. Kuster MS, Wood GA, Stachowiak GW, Gächter A. Joint load considerations in total knee replacement. J Bone Joint Surg Br. 1997 Jan;79(1):109-13. doi: 10.1302/0301-620x.79b1.6978.
  41. Sowers MR, McConnell D, Jannausch M, Buyuktur AG, Hochberg M, Jamadar DA. Estradiol and its metabolites and their association with knee osteoarthritis. Arthritis Rheum. 2006 Aug;54(8):2481-7. doi: 10.1002/art.22005.
  42. Valdes AM, Van Oene M, Hart DJ, Surdulescu GL, Loughlin J, Doherty M, Spector TD. Reproducible genetic associations between candidate genes and clinical knee osteoarthritis in men and women. Arthritis Rheum. 2006 Feb;54(2):533-9. doi: 10.1002/art.21621. Erratum in: Arthritis Rheum. 2009 Jan;60(1):178.
  43. Jin SY, Hong SJ, Yang HI, Park SD, Yoo MC, Lee HJ, Hong MS, Park HJ, Yoon SH, Kim BS, Yim SV, Park HK, Chung JH. Estrogen receptor-alpha gene haplotype is associated with primary knee osteoarthritis in Korean population. Arthritis Res Ther. 2004;6(5):R415-21. doi: 10.1186/ar1207.
  44. Cooper C, Egger P, Coggon D, Hart DJ, Masud T, Cicuttini F, Doyle DV, Spector TD. Generalized osteoarthritis in women: pattern of joint involvement and approaches to definition for epidemiological studies. J Rheumatol. 1996 Nov;23(11):1938-42.
  45. Szoeke CEI, Cicuttini FM, Guthrie JR, Clark MS, Dennerstein L. Factors affecting the prevalence of osteoarthritis in healthy middle-aged women: data from the longitudinal Melbourne Women's Midlife Health Project. Bone. 2006 Nov;39(5):1149-1155. doi: 10.1016/j.bone.2006.05.016.
  46. Nadkar MY, Samant RS, Vaidya SS, Borges NE. Relationship between osteoarthritis of knee and menopause. J Assoc Physicians India. 1999 Dec;47(12):1161-3.
  47. Bergink AP, van Meurs JB, Loughlin J, Arp PP, Fang Y, Hofman A, van Leeuwen JP, van Duijn CM, Uitterlinden AG, Pols HA. Estrogen receptor alpha gene haplotype is associated with radiographic osteoarthritis of the knee in elderly men and women. Arthritis Rheum. 2003 Jul;48(7):1913-22. doi: 10.1002/art.11046.
  48. Herrero-Beaumont G, Roman-Blas JA, Castañeda S, Jimenez SA. Primary osteoarthritis no longer primary: three subsets with distinct etiological, clinical, and therapeutic characteristics. Semin Arthritis Rheum. 2009 Oct;39(2):71-80. doi: 10.1016/j.semarthrit.2009.03.006.
  49. Hanna F, Ebeling PR, Wang Y, O'Sullivan R, Davis S, Wluka AE, Cicuttini FM. Factors influencing longitudinal change in knee cartilage volume measured from magnetic resonance imaging in healthy men. Ann Rheum Dis. 2005 Jul;64(7):1038-42. doi: 10.1136/ard.2004.029355.
  50. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004 Jan;81(1):19-25. doi: 10.1016/j.fertnstert.2003.10.004.
  51. Zawadzki JK. DunaifA Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. Polycystic Ovary Syndrome 1995;377-84.
  52. Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE); Androgen Excess and PCOS Society (AES). AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1. Endocr Pract. 2015 Nov;21(11):1291-300. doi: 10.4158/EP15748.DSC.
  53. Kabakchieva P, Georgiev T, Gateva A, Hristova J, Kamenov Z. Polycystic ovary syndrome and (pre)osteoarthritis: assessing the link between hyperandrogenism in young women and cartilage oligomeric matrix protein as a marker of cartilage breakdown. Clin Rheumatol. 2021 May 4. Doi: 10.1007/s10067-021-05753-0.
  54. Velasquez MT, Katz JD. Osteoarthritis: another component of metabolic syndrome? Metab Syndr Relat Disord. 2010 Aug;8(4):295-305. doi: 10.1089/met.2009.0110.
  55. Ramly B, Afiqah-Aleng N, Mohamed-Hussein ZA. Protein-Protein Interaction Network Analysis Reveals Several Diseases Highly Associated with Polycystic Ovarian Syndrome. Int J Mol Sci. 2019 Jun 18;20(12):2959. doi: 10.3390/ijms20122959.
  56. Sanchez-Santos, M. T., Rubin, K. H., Glintborg, D., Andersen, M. S., Kluzek, S., & Abrahamsen, B. (2018). Prevalence and incidence of clinically diagnosed knee, hip and hand osteoarthritis in women with polycystic ovary syndrome: a National Register-Based Study. Osteoarthritis and Cartilage, 26, S200. doi: 10.1016/j.joca.2018.02.425.
  57. Hussain SM, Cicuttini FM, Bell RJ, Robinson PJ, Davis SR, Giles GG, Graves S, Milne RL, Wang Y. Incidence of total knee and hip replacement for osteoarthritis in relation to circulating sex steroid hormone concentrations in women. Arthritis Rheumatol. 2014 Aug;66(8):2144-51. doi: 10.1002/art.38651.
  58. Lewandowski KC, Komorowski J, O'Callaghan CJ, Tan BK, Chen J, Prelevic GM, Randeva HS. Increased circulating levels of matrix metalloproteinase-2 and -9 in women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Mar;91(3):1173-7. doi: 10.1210/jc.2005-0648.
  59. Giannelli G, Erriquez R, Iannone F, Marinosci F, Lapadula G, Antonaci S. MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in patients with rheumatoid arthritis and psoriatic arthritis. Clin Exp Rheumatol. 2004 May-Jun;22(3):335-8.
  60. Gruber BL, Sorbi D, French DL, Marchese MJ, Nuovo GJ, Kew RR, Arbeit LA. Markedly elevated serum MMP-9 (gelatinase B) levels in rheumatoid arthritis: a potentially useful laboratory marker. Clin Immunol Immunopathol. 1996 Feb;78(2):161-71. doi: 10.1006/clin.1996.0025.
  61. Zeng GQ, Chen AB, Li W, Song JH, Gao CY. High MMP-1, MMP-2, and MMP-9 protein levels in osteoarthritis. Genet Mol Res. 2015 Nov 23;14(4):14811-22. doi: 10.4238/2015.November.18.46.
  62. Baka S, Zourla K, Kouskouni E, Makrakis E, Demeridou S, Tzanakaki D, Hassiakos D, Creatsas G. Matrix metalloproteinases 2 and 9 and their tissue inhibitors in the follicular fluid of patients with polycystic ovaries undergoing in vitro fertilisation. In Vivo. 2010 May-Jun;24(3):293-6.
  63. Goldman S, Shalev E. MMPS and TIMPS in ovarian physiology and pathophysiology. Front Biosci. 2004 Sep 1;9:2474-83. doi: 10.2741/1409.
  64. Lahav-Baratz S, Kraiem Z, Shiloh H, Koifman M, Ishai D, Dirnfeld M. Decreased expression of tissue inhibitor of matrix metalloproteinases in follicular fluid from women with polycystic ovaries compared with normally ovulating patients undergoing in vitro fertilization. Fertil Steril. 2003 Mar;79(3):567-71. doi: 10.1016/s0015-0282(02)04838-0.
  65. Chen Z, Wei H, Zhao X, Xin X, Peng L, Ning Y, Wang Y, Lan Y, Zhang Q. Metformin treatment alleviates polycystic ovary syndrome by decreasing the expression of MMP-2 and MMP-9 via H19/miR-29b-3p and AKT/mTOR/autophagy signaling pathways. J Cell Physiol. 2019 Nov;234(11):19964-19976. doi: 10.1002/jcp.28594.
  66. Galasso O, Familiari F, De Gori M, Gasparini G. Recent findings on the role of gelatinases (matrix metalloproteinase-2 and -9) in osteoarthritis. Adv Orthop. 2012;2012:834208. doi: 10.1155/2012/834208.
  67. Smith RK, Heinegård D. Cartilage oligomeric matrix protein (COMP) levels in digital sheath synovial fluid and serum with tendon injury. Equine Vet J. 2000 Jan;32(1):52-8. doi: 10.2746/042516400777612053.
  68. Bruyere O, Collette J, Kothari M, Zaim S, White D, Genant H, Peterfy C, Burlet N, Ethgen D, Montague T, Dabrowski C, Reginster JY. Osteoarthritis, magnetic resonance imaging, and biochemical markers: a one year prospective study. Ann Rheum Dis. 2006 Aug;65(8):1050-4. doi: 10.1136/ard.2005.045914.
  69. Vilím V, Olejárová M, Machácek S, Gatterová J, Kraus VB, Pavelka K. Serum levels of cartilage oligomeric matrix protein (COMP) correlate with radiographic progression of knee osteoarthritis. Osteoarthritis Cartilage. 2002 Sep;10(9):707-13. doi: 10.1053/joca.2002.0819.
  70. Singh S, Shahi U, Kumar D, Shahi NT (2014) Serum Cartilage Oligomeric Matrix Protein: Tool for early diagnosis and grading of severity of primary knee osteoarthritis. Int J Osteol Orthop 1: 1-7.
  71. Awadallah AM, Gehan HS, Tarek MK (2010) Serum level of cartilage oligomeric matrix protein as a screening modality for osteoarthritis among knee joint pain patients. Journal of American Science 6(12).
  72. Clark AG, Jordan JM, Vilim V, Renner JB, Dragomir AD, Luta G, Kraus VB. Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project. Arthritis Rheum. 1999 Nov;42(11):2356-64. doi: 10.1002/1529-0131(199911)42:11<2356::AID-ANR14>3.0.CO;2-R
  73. Vos T, Abajobir AA, Abbafati C, Abbas KM, Abate KH, Abd-Allah F et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017; 390:1211–1259.